Adi Diab

Adi Diab is a melanoma oncologist who has led clinical development of relatlimab (anti-LAG-3) and contributed to the RELATIVITY-047 trial demonstrating superior progression-free survival with relatlimab plus nivolumab versus nivolumab alone in previously untreated advanced melanoma — marking the first approval of a LAG-3 inhibitor. He investigates the combination of innate and adaptive immune checkpoints including anti-CD47 in solid tumors. His research explores biomarkers of LAG-3 pathway activity and combination immunotherapy sequencing in melanoma.